Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Susan Hawrylkiw

Nurse Practitioner, Family Phoenix, AZ Nurse Practitioner

NPI 1457427445 CMS profile 10589663

4530 E Muirwood Dr, St 11, Phoenix, AZ 85048

Open in the dashboard

General payments

$21,820

1,033 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Hawrylkiw of Phoenix, AZ is reported in the CMS Open Payments database as having received $21,820 across 1,033 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,256 213
2024 General $4,331 201
2023 General $3,997 206
2022 General $4,381 180
2021 General $4,856 233

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Hawrylkiw
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Susan Hawrylkiw were reported at $4,256. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Susan Hawrylkiw Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $4,856 $124 $35–$379 $132
2022 $4,381 $141 $44–$430 $149
2023 $3,997 $154 $49–$476 $160
2024 $4,331 $165 $51–$504 $164
2025 $4,256 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $5,032 346 payments
  2. Abbott Laboratories $1,463 20 payments
  3. Medtronic, Inc. $1,320 15 payments
  4. Eisai Inc. $1,139 40 payments
  5. Lilly USA, LLC $959 59 payments
  6. Novartis Pharmaceuticals Corporation $847 46 payments
  7. Biogen, Inc. $783 32 payments
  8. Genentech USA, Inc. $736 22 payments
  9. Amgen Inc. $705 27 payments
  10. Alexion Pharmaceuticals, Inc. $633 21 payments
  11. Other $8,205 405 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $20,271 1,023 payments
  2. Travel and Lodging $1,419 7 payments
  3. Education $117 2 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13 1 payment
Products named General payments · program years 2021–2025
  1. BOTOX Botox Therapeutic $2,163 163 payments
  2. UBRELVY $1,407 111 payments
  3. QULIPTA $1,235 94 payments
  4. PERCEPT PC BRAINSENSE $1,142 13 payments
  5. Infinity DBS Pulse Generators $1,134 12 payments
  6. Leqembi $1,102 38 payments
  7. AIMOVIG $670 25 payments
  8. NURTEC ODT $580 16 payments
  9. BOTOX Hyperhydrosis $574 49 payments
  10. ZEPOSIA $560 32 payments
  11. Other $13,351 659 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,312

Median for Nurse Practitioner: 389

Drug cost

$165,767

Median for Nurse Practitioner: $21,885

Branded share of claims

39.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 16 $79,834
Rytary Carbidopa/Levodopa Brand 31 $27,511
Emgality Pen Galcanezumab-Gnlm Brand 13 $9,190
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 143 $8,158
Aimovig Autoinjector Erenumab-Aooe Brand 11 $7,857
Carbidopa-Levodopa Carbidopa/Levodopa Brand 148 $7,808
Primidone Generic 75 $4,024
Gabapentin Generic 168 $2,852
Pregabalin Generic 41 $1,726
Memantine Hcl Generic 48 $1,640

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$891 — —
Leqembi
$625 — —
DUOPA
$223 — —
VUMERITY
$187 — —
UBRELVY
$185 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

1,033 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record